Drug Interactions in Dermatological Practice. What Should be Considered when Treating Patients with Multimorbidity?
Abstract
In dermatological practice, physicians are increasingly encountering patients with multimorbidity who are undergoing polypharmacy. This requires an understanding of the potential interactions between patients’ existing medications and the prescribed dermatological pharmacotherapy. Data from registries of drug-induced complications indicate that adverse effects commonly associated with adverse events often involve medications used in polytherapy. This article compiles the most frequent interactions encountered in dermatological practice.
Read the paper
Related studies
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Tocilizumab in patients with severe COVID-19: a retrospective cohort study
- A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A cohort study
- Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study
- Are noise and air pollution related to the incidence of dementia? A cohort study in London, England
- Long COVID symptoms and duration in SARS-CoV-2 positive children — a nationwide cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.